Table 6. Fisher's exact test result to compare categorical patient characteristics between iSUV low and high groups (n=179).

	iSUV
	Low (<12.7)	High (>=12.7)	P-value
Primary Site
Esophagus	9(21.4%)	33(78.6%)	<0.0001
AEG1	40(50.6%)	39(49.4%)
AEG2	39(70.9%)	16(29.1%)
AEG3	1(25%)	3(75%)
Baseline Tumor Status
T1	9(100%)	0(0%)	<0.0001
T2	14(93.3%)	1(6.7%)
T3	63(44.4%)	79(55.6%)
T4	3(25%)	9(75%)
TX	0(0%)	2(100%)
Baseline Lymph node Status
N0	38(71.7%)	15(28.3%)	0.0001
N+	50(39.7%)	76(60.3%)
NX	1(100%)	0(0%)
Metastatic Status
M0	75(54.3%)	63(45.7%)	0.0590
M1a	6(31.6%)	13(68.4%)
M1b	8(34.8%)	15(65.2%)
Baseline Stage
I	7(100%)	0(0%)	<0.0001
IIA	29(69%)	13(31%)
IIB	7(87.5%)	1(12.5%)
III	32(39.5%)	49(60.5%)
IVA	6(31.6%)	13(68.4%)
IVB	8(34.8%)	15(65.2%)
Tumor Histology
Adenocarcinoma	80(58%)	58(42%)	<0.0001
Squamous cell carcinoma	9(21.4%)	33(78.6%)
Tumor Grade
G1 well diff.	1(50%)	1(50%)	0.8249
G2 moderately diff.	38(47.5%)	42(52.5%)
G3 poorly diff.	50(51.5%)	47(48.5%)
GX undetermined	0(0%)	1(100%)
Induction Chemotherapy
Yes	36(50%)	36(50%)	1.0
No	53(49.1%)	55(50.9%)
Chemoradiotherapy Agents
Platinum + Fluoropyrimidine	23(51.1%)	22(48.9%)	0.9133
Taxane + Fluoropyrimidine	51(50.5%)	50(49.5%)
Others	14(45.2%)	17(54.8%)
Unknown	1(33.3%)	2(66.7%)
Clinical CR after chemoradiation
Achieved	70 (60.3%)	46 (39.7%)	0.0002
Not achieved	13 (27.7%)	34 (72.3%)

iSUV denotes standardized uptake value;